Status:
UNKNOWN
Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)
Lead Sponsor:
Ministry of Science and Technology of the People´s Republic of China
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The study is a single-arm, open-label, multicenter clinical trial.The primary purpose of this trial is to evaluate the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic ...
Detailed Description
The study is a single-arm, open-label, multicenter clinical trial.A total of 220 patients (Age≥18years) with acute ischemic stroke treated with intravascular thrombolysis, mechanical thrombolysis, ang...
Eligibility Criteria
Inclusion
- Age≥18 years.
- Acute ischemic stroke.
- Treated with endovascular treatment, including intra-arterial thrombolysis, mechanical thrombectomy, and angioplasty.
- Written informed consent obtained from patient or patient's legally authorized representative.
Exclusion
- Failed to vascular recanalization (mTICI≤1).
- Diagnosis of intracranial hemorrhagic disease, such as intracranial hemorrhage, subarachnoid hemorrhage and so on.
- Known coagulopathy, Systemic Bleeding Tendency, or baseline platelet count \< 100000/mm3.
- History of chronic hepatopathy, liver and kidney dysfunction, elevating ALT (\> 3 times normal upper limit), elevating serum creatinine (\> 2 times normal upper limit).
- Patients with severe hypertension (systolic blood pressure \> 200mmHg or diastolic blood pressure \> 110mmHg).
- Known drug or food allergy.
- Used other Glycoprotein IIb/IIIa receptor antagonists.
- Contraindications for DSA, severe contrast media allergy or iodine contrast media absolute contraindications.
- Childbearing age women whose pregnancy tests were negative refused to take effective contraception. Pregnant or lactating or positive pregnancy test on admission.
- Incapable to follow this study for mental illness, cognitive or emotional disorder.
- The researchers do not consider the participants appropriate to get into this study.
Key Trial Info
Start Date :
April 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT03844594
Start Date
April 6 2019
End Date
December 31 2020
Last Update
June 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070